GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » EV-to-FCF

CHRO (Channel Therapeutics) EV-to-FCF : -1.93 (As of Mar. 19, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Channel Therapeutics's Enterprise Value is $10.56 Mil. Channel Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-5.48 Mil. Therefore, Channel Therapeutics's EV-to-FCF for today is -1.93.

The historical rank and industry rank for Channel Therapeutics's EV-to-FCF or its related term are showing as below:

CHRO' s EV-to-FCF Range Over the Past 10 Years
Min: -22.36   Med: 0   Max: 0
Current: -2.04

CHRO's EV-to-FCF is ranked worse than
100% of 415 companies
in the Biotechnology industry
Industry Median: 4.08 vs CHRO: -2.04

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-19), Channel Therapeutics's stock price is $1.59. Channel Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.850. Therefore, Channel Therapeutics's PE Ratio (TTM) for today is At Loss.


Channel Therapeutics EV-to-FCF Historical Data

The historical data trend for Channel Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics EV-to-FCF Chart

Channel Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - -

Channel Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -4.05 -1.24 -0.94

Competitive Comparison of Channel Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Channel Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Channel Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Channel Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Channel Therapeutics's EV-to-FCF falls into.



Channel Therapeutics EV-to-FCF Calculation

Channel Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10.557/-5.479
=-1.93

Channel Therapeutics's current Enterprise Value is $10.56 Mil.
Channel Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Channel Therapeutics  (AMEX:CHRO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Channel Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.59/-1.850
=At Loss

Channel Therapeutics's share price for today is $1.59.
Channel Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.850.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Channel Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Channel Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Channel Therapeutics Headlines